New obesity drug GV101 shows promise in Mid-Stage trial
NCT ID NCT06979505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed phase 2 trial tested different doses of the drug GV101 against a placebo for weight loss in 131 healthy adults with obesity. The main goal was to see how much weight participants lost after 16 weeks. Researchers compared the average weight change in each dose group to the placebo group to determine if GV101 is effective and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GV101
- What this could lead to
- If successful, GV101 could offer a new medication option for weight loss in people with obesity.
- What could go wrong
- This is a phase 2 trial with only 131 participants, so results may not apply to everyone. Weight loss drugs can have side effects and may not work for all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Research Institute - Ogden
Ogden, Utah, 84405, United States
-
Arizona Clinical Trials
Tucson, Arizona, 85712, United States
-
Catalina Research Institute, LLC
Montclair, California, 91763, United States
-
Chrysalis Clinical Research
St. George, Utah, 84790, United States
-
Coastal Research Institute, LLC
Fayetteville, North Carolina, 28304, United States
-
Encompass Clinical Research
Spring Valley, California, 91978, United States
-
Hadassah Medical Center Ein Karem
Jerusalem, Israel, Israel
-
Hasharon Hospital
Petah Tikva, Israel, Israel
-
Hassman Research Institute
Berlin, New Jersey, 08009, United States
-
Kansas City Research Institute
Kansas City, Missouri, 64131, United States
-
Lakeview Clinical Research, LLC
Guntersville, Alabama, 35976, United States
-
Lillestol Research, LLC
Fargo, North Dakota, 58104, United States
-
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
Louisville, Kentucky, 40213, United States
-
Mercury Street Medical
Butte, Montana, 59701, United States
-
Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel, Israel
-
Sheba Medical Center
Tel Litwinsky, Israel, Israel
-
Study Metrix Research
City of Saint Peters, Missouri, 63303, United States
-
Tandem Clinical Research
Marrero, Louisiana, 70072, United States
-
Velocity Clinical Research - Cleveland
Cleveland, Ohio, 44122, United States
-
Velocity Clinical Research - Dallas
Dallas, Texas, 75230, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can a daily probiotic boost metabolic health and body confidence?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?